Group 8 Bimetallic Complexes for Light-Driven Cancer Therapy

The incorporation of a second metal center with different biological targets and complementary physicochemical properties into metal-based compounds represents a promising strategy to enhance anticancer efficacy and overcome the limitations of conventional monometallic drugs. In recent years, increasing attention has been devoted to multitarget anticancer agents, including heterometallic complexes. This review provides an overview of recent advances in Group 8 bimetallic complexes containing iron, ruthenium, or osmium for light-driven cancer therapy. Particular emphasis is placed on their molecular design, photophysical and photochemical properties, mechanisms of action, and anticancer activity. The influence of the two metal centers on photoactivation, generation of reactive species, cellular targets, and therapeutic efficacy is discussed, together with emerging structure–activity relationships. Finally, current challenges and future perspectives for the development of these complexes as photoactivated anticancer agents are highlighted.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2026-11-18
DOI
https://doi.org/10.3390/pharmaceutics18111489
Primary Topic
Metal complexes synthesis and properties
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Group 8 Bimetallic Complexes for Light-Driven Cancer Therapy

Marta Martı́nez-Alonso, María Jesús Moran
2 links
Pharmaceutics
Metal complexes synthesis and properties
article

Group 8 Bimetallic Complexes for Light-Driven Cancer Therapy

Marta Martı́nez-Alonso, María Jesús Moran
article en

Abstract

The incorporation of a second metal center with different biological targets and complementary physicochemical properties into metal-based compounds represents a promising strategy to enhance anticancer efficacy and overcome the limitations of conventional monometallic drugs. In recent years, increasing attention has been devoted to multitarget anticancer agents, including heterometallic complexes. This review provides an overview of recent advances in Group 8 bimetallic complexes containing iron, ruthenium, or osmium for light-driven cancer therapy. Particular emphasis is placed on their molecular design, photophysical and photochemical properties, mechanisms of action, and anticancer activity. The influence of the two metal centers on photoactivation, generation of reactive species, cellular targets, and therapeutic efficacy is discussed, together with emerging structure–activity relationships. Finally, current challenges and future perspectives for the development of these complexes as photoactivated anticancer agents are highlighted.

PharmaceuticsVol. 18(11)
Universidad Rey Juan Carlos (ES), Universidad de Burgos (ES)
Good health and well-being
Metal complexes synthesis and properties
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon